It's also called adriamycin, abbreviated as Dox. Is it commonly used in clinical practice? Is there any resistance to this drug? Anyone who has some experience with this drug, please kindly share with me some of these details.
Hi
I treated K562 and HL60 leukemia cells with 10 - 20 uM Doxorubicin for 24 - 48 hours and measured apoptosis with AnnexinV/PI and/or cleaved-caspase3 induction by western. It is a good range to observe apoptosis induction. Alessandro
I would recommend doing a dose curve for your drug to determine the most effective range for your treatment. The responsiveness to the drug is based on your cell line you are working on.
Adriamycin interferes with DNA replication by intercalating into DNA and blocking progression of topoisomerase II. It is cytotoxic because it stabilizes topoisomerase II in complex with broken DNA chain preventing DNA double helix from being repaired and stopping replication. Resistance comes from up regulating drug efflux pump genes and down regulating topoisomerase II along with changes to DNA repair genes such as BRCA1, TOP2A, BRCA2, TP53, and ATM.
Dear Zhiming,
a colleague of mine treated RKO colon cancer cells with 1uM Doxo. When ~50% confluent at timepoint of treatment, after 24 h ca. 50% of cells died. Of course, reaction depends on confluency of the populatioon ;)
Hi
I have worked consistently with doxorubicin in vitro and in vivo. This drug is consistently used in clinical treatment of patients. Doxorubicin hydrochloride belongs to the general group of chemotherapy drugs known as anthracycline antibiotics. It is used to treat non–Hodgkin’s lymphoma, multiple myeloma, acute leukemias, and cancers of the breast, adrenal cortex, endometrium, lung, and ovary.cancer.
Clinical dose is 1.5mg/kg and MTD is 6mg/kg. This drug can be used singly or in combination with other therapeutic drugs in vivo and in vitro.
whatexactly are you needing to know?
- Badges
- Science topic
- Similar topics
- Entomology
- Resistance